News | January 03, 2022
U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The drug will be marketed under the brand name Molnaflu
The proposed scheme to include low-income NRIs under Ayushman Bharat (PM-JAY) would ensure life-long coverage for each individual along with their spouses
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)